Prognostic Value of a Three-DNA Methylation Biomarker in Patients with Soft Tissue Sarcoma
Table 3
Results of Kaplan–Meier and ROC analysis in different groups based on different clinical characteristics.
Regrouping factors
Group
Sample size
Kaplan–Meier Log rank value
Kaplan–Meier Breslow value
AUC
95% CI
3-meth
MST1-meth
3-meth
MST1-meth
3-meth
MST1-meth
3-meth
MST1-meth
Sex
Female
140
4.02E−07
1.70E−02
2.45E−07
1.03E−02
0.773
0.657
0.676–0.870
0.535–0.779
Male
117
1.69E−05
7.63E−03
1.22E−05
6.34E−03
0.785
0.636
0.665–0.915
0.490–0.782
Age at diagnosis
<61
128
1.10E−04
1.87E−04
5.26E−05
3.13E−04
0.734
0.714
0.599–0.870
0.572–0.856
≥61
129
2.11E−06
1.07E−01
2.54E−07
7.01E−02
0.815
0.599
0.721–0.908
0.478–0.720
Tissue of origin
Connective soft tissue
114
2.19E−03
3.21E−01
8.44E−04
2.94E−01
0.800
0.483
0.677–0.923
0.299–0.666
Retroperitoneum
99
9.24E−05
1.69E−04
6.75E−05
3.10E−04
0.787
0.701
0.661–0.914
0.574–0.827
Other tissues
44
8.68E−04
1.44E−01
6.19E−04
1.32E−01
0.798
0.692
0.655–0.941
0.504–0.881
Histological type
Leiomyosarcoma
104
3.66E−05
1.15E−02
3.49E−05
1.17E−02
0.792
0.657
0.665–0.920
0.502–0.812
Liposarcoma
59
2.42E−04
1.45E−04
2.48E−04
1.92E−04
0.790
0.753
0.626–0.953
0.616–0.890
Other subtypes
94
7.57E−05
4.36E−02
3.19E−05
3.73E−02
0.806
0.579
0.692–0.919
0.402–0.756
Treatment type
Pharmaceutical
137
5.17E−07
2.75E−04
4.24E−07
4.51E−04
0.769
0.673
0.659–0.879
0.545–0.800
Radiation
120
2.75E−06
8.08E−02
2.20E−06
7.25E−02
0.801
0.6100
0.698–0.905
0.471–0.750
To be mentioned, 3-meth is the biomarker identified in this paper. The Z-test was used to assess whether the AUC of the 3-DNA methylation biomarker is higher than the AUC of the MST1 methylation biomarker. “” represents the value of Z-test being less than 0.001, which illustrated that the AUC of our 3-DNA methylation biomarker was significantly higher than the MST1 methylation biomarker.
